Innate Immunity in Cancer Biology and Therapy.
cancer therapy
chimeric antigen receptors
cytokines
immune checkpoint inhibitors
innate immunity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Jul 2023
08 Jul 2023
Historique:
received:
21
05
2023
revised:
05
07
2023
accepted:
05
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Immunotherapies including adaptive immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells, have developed the treatment of cancer in clinic, and most of them focus on activating T cell immunity. Although these strategies have obtained unprecedented clinical responses, only limited subsets of cancer patients could receive long-term benefits, highlighting the demand for identifying novel targets for the new era of tumor immunotherapy. Innate immunity has been demonstrated to play a determinative role in the tumor microenvironment (TME) and influence the clinical outcomes of tumor patients. A thorough comprehension of the innate immune cells that infiltrate tumors would allow for the development of new therapeutics. In this review, we outline the role and mechanism of innate immunity in TME. Moreover, we discuss innate immunity-based cancer immunotherapy in basic and clinical studies. Finally, we summarize the challenges in sufficiently motivating innate immune responses and the corresponding strategies and measures to improve anti-tumor efficacy. This review could aid the comprehension of innate immunity and inspire the creation of brand-new immunotherapies for the treatment of cancer.
Identifiants
pubmed: 37510993
pii: ijms241411233
doi: 10.3390/ijms241411233
pmc: PMC10379825
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 32200745, 82073752, 81773620 and 82002915
Organisme : Shanghai Sailing Program
ID : 21YF1401900, 20YF1402800
Organisme : Scientific and Innovative Action Plan of Shanghai
ID : 20S11904700, 20JC1411000 and 20S11906100
Références
Antib Ther. 2022 Feb 23;5(1):73-83
pubmed: 35372786
Am J Physiol Regul Integr Comp Physiol. 2012 May;302(9):R1067-75
pubmed: 22422663
Clin Cancer Res. 2009 Nov 15;15(22):7029-35
pubmed: 19903777
Breast Cancer Res Treat. 2012 Jan;131(2):483-90
pubmed: 21971729
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35022194
Cell Res. 2020 Jul;30(7):610-622
pubmed: 32367039
J Clin Invest. 2016 Jun 1;126(6):2341-55
pubmed: 27183388
J Clin Invest. 2018 Dec 3;128(12):5647-5662
pubmed: 30352428
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Clin Transl Oncol. 2023 Jun;25(6):1545-1553
pubmed: 36587109
Heart. 2021 Nov;107(21):1694-1703
pubmed: 33722826
Adv Drug Deliv Rev. 2019 Feb 15;141:67-91
pubmed: 30201522
Nat Med. 2019 May;25(5):814-824
pubmed: 30962585
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33495297
Mol Immunol. 2019 Jun;110:69-76
pubmed: 29269005
Cancers (Basel). 2019 Jun 23;11(6):
pubmed: 31234588
Blood Adv. 2020 May 12;4(9):1950-1964
pubmed: 32384544
Cancer Res. 2006 Dec 1;66(23):11432-40
pubmed: 17145890
Front Immunol. 2020 Jul 02;11:1347
pubmed: 32714329
Cancer Cell. 2023 Mar 13;41(3):490-504
pubmed: 36868224
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
J Clin Invest. 2019 Sep 3;129(9):3499-3510
pubmed: 31478911
Cancer Cell. 2014 Jan 13;25(1):37-48
pubmed: 24434209
Cancer Immunol Res. 2013 Oct;1(4):201-9
pubmed: 24777851
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100
pubmed: 32934330
Semin Cancer Biol. 2013 Jun;23(3):141-8
pubmed: 23485549
Front Immunol. 2020 Sep 02;11:2100
pubmed: 32983165
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Trends Cancer. 2016 Dec;2(12):747-757
pubmed: 28626801
Front Immunol. 2020 Jul 08;11:1276
pubmed: 32733446
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810248
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
Cancer Immunol Immunother. 2017 Oct;66(10):1367-1375
pubmed: 28623459
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Nat Rev Cancer. 2016 Mar;16(3):131-44
pubmed: 26911188
Int J Biol Sci. 2021 Jul 25;17(13):3281-3287
pubmed: 34512146
Adv Mater. 2022 Oct;34(41):e2206121
pubmed: 36017886
Nat Immunol. 2021 Jul;22(7):851-864
pubmed: 34099918
Immunology. 2011 Jun;133(2):206-20
pubmed: 21426339
Biomed Pharmacother. 2023 Aug;164:114996
pubmed: 37311281
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
Front Immunol. 2019 Sep 11;10:2180
pubmed: 31572388
J Immunol. 2007 Nov 15;179(10):6881-8
pubmed: 17982079
Blood. 2011 Aug 18;118(7):1877-84
pubmed: 21680794
Cancer Res. 2021 Mar 1;81(5):1201-1208
pubmed: 33203697
Cell Rep. 2016 Feb 23;14(7):1723-1734
pubmed: 26876174
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Histopathology. 2013 Aug;63(2):225-33
pubmed: 23738752
Oncogene. 2017 Jan 26;36(4):482-490
pubmed: 27375023
J Immunol. 2016 Mar 1;196(5):2410-23
pubmed: 26829987
Signal Transduct Target Ther. 2021 Oct 7;6(1):362
pubmed: 34620838
J Hematol Oncol. 2020 Dec 7;13(1):168
pubmed: 33287875
World J Clin Cases. 2023 Apr 16;11(11):2386-2395
pubmed: 37123307
Discov Oncol. 2023 May 23;14(1):77
pubmed: 37217620
Blood. 2014 Oct 30;124(18):2824-33
pubmed: 25049283
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Nat Rev Mol Cell Biol. 2020 Sep;21(9):501-521
pubmed: 32424334
J Med Virol. 2023 Jan;95(1):e28259
pubmed: 36305096
Nat Biotechnol. 2023 Apr;41(4):532-540
pubmed: 36316485
Scand J Immunol. 2002 Mar;55(3):221-8
pubmed: 11940227
Curr Opin Oncol. 2018 Sep;30(5):332-337
pubmed: 29994903
J Exp Med. 2011 Sep 26;208(10):1949-62
pubmed: 21930770
J Biol Chem. 2016 Aug 26;291(35):18139-47
pubmed: 27402834
Nat Rev Immunol. 2012 Apr;12(4):237
pubmed: 22545289
Converg Sci Phys Oncol. 2017;3:
pubmed: 30079253
Nat Commun. 2014;5:3016
pubmed: 24398568
Nat Immunol. 2018 Oct;19(10):1093-1099
pubmed: 30201992
Anticancer Agents Med Chem. 2020;20(17):2025-2040
pubmed: 32628596
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
J Lipid Res. 2016 Sep;57(9):1659-69
pubmed: 27436590
Eur J Immunol. 2010 Jan;40(1):22-35
pubmed: 19941314
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Nat Commun. 2017 Sep 19;8(1):593
pubmed: 28928446
J Breast Cancer. 2013 Mar;16(1):55-9
pubmed: 23593082
J Thorac Dis. 2017 Feb;9(2):E168-E174
pubmed: 28275508
Cancer Immunol Res. 2019 Feb;7(2):257-268
pubmed: 30659054
Cells. 2020 Jul 22;9(8):
pubmed: 32707982
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Int J Biol Sci. 2022 Mar 21;18(6):2609-2626
pubmed: 35414783
Cancer Discov. 2020 Jan;10(1):26-39
pubmed: 31852718
EBioMedicine. 2019 Jun;44:361-374
pubmed: 31085102
Immunity. 2021 May 11;54(5):875-884
pubmed: 33979585
Cancers (Basel). 2023 May 16;15(10):
pubmed: 37345111
Theranostics. 2021 Jan 1;11(3):1016-1030
pubmed: 33391518
Cell Mol Immunol. 2021 Jun;18(6):1607-1609
pubmed: 33854207
Cell. 2017 Feb 9;168(4):724-740
pubmed: 28187291
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Cell Mol Immunol. 2020 Aug;17(8):807-821
pubmed: 32612154
Clin Cancer Res. 2009 Nov 15;15(22):7036-44
pubmed: 19903780
Nat Immunol. 2018 Jul;19(7):723-732
pubmed: 29915296
Transl Res. 2017 Sep;187:32-43
pubmed: 28651074
Trends Mol Med. 2015 Jan;21(1):24-33
pubmed: 25440090
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Cell Commun Signal. 2022 Apr 7;20(1):44
pubmed: 35392976
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119
pubmed: 35361234
Eur J Immunol. 2015 Jan;45(1):119-29
pubmed: 25312824
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Stem Cells. 2018 Jul;36(7):990-1003
pubmed: 29604141
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Cell Mol Immunol. 2021 Apr;18(4):792-804
pubmed: 32999455
Ann Surg Oncol. 2012 Jan;19(1):217-24
pubmed: 21638095
Life Sci. 2023 Sep 1;328:121857
pubmed: 37307965
Cell Mol Immunol. 2019 Jan;16(1):28-39
pubmed: 30002451
Blood. 2006 Mar 1;107(5):2112-22
pubmed: 16269622
Mucosal Immunol. 2014 Jul;7(4):842-56
pubmed: 24280935
J Exp Med. 2013 May 6;210(5):917-31
pubmed: 23589566
J Exp Med. 2004 Feb 16;199(4):567-79
pubmed: 14970182
Mol Cancer Ther. 2021 Jun;20(6):961-974
pubmed: 33850005
Nat Immunol. 2012 Sep;13(9):832-42
pubmed: 22842346
Immunology. 2007 Jun;121(2):258-65
pubmed: 17346281
Ann Oncol. 2007 Feb;18(2):226-32
pubmed: 17116643
Nat Immunol. 2022 Mar;23(3):371-379
pubmed: 35228695
J Hematol Oncol. 2022 Mar 18;15(1):28
pubmed: 35303904
Eur J Immunol. 2016 Feb;46(2):329-39
pubmed: 26542182
Cancer Discov. 2011 Oct;1(5):430-41
pubmed: 22408746
Nat Commun. 2019 Jun 21;10(1):2735
pubmed: 31227713
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
Cancer Cell. 2015 Jan 12;27(1):12-4
pubmed: 25584891
Cell Mol Immunol. 2021 Feb;18(2):279-293
pubmed: 33177696
Adv Drug Deliv Rev. 2022 Mar;182:114112
pubmed: 35085624
Cancer Lett. 2019 Mar 1;444:1-8
pubmed: 30508568
Sci China Life Sci. 2019 May;62(5):633-639
pubmed: 30796720
J Clin Invest. 2014 Jan;124(1):99-110
pubmed: 24292706
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Nat Commun. 2019 Sep 25;10(1):4353
pubmed: 31554795
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Cancer Immunol Immunother. 2019 Feb;68(2):163-174
pubmed: 30315349
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Immunol Immunother. 2015 Feb;64(2):225-35
pubmed: 25344904
Biochem Pharmacol. 2023 Jul;213:115596
pubmed: 37201875
Clin Cancer Res. 2021 Jul 1;27(13):3661-3673
pubmed: 33771857
Signal Transduct Target Ther. 2021 May 31;6(1):201
pubmed: 34054126
J Hematol Oncol. 2020 Aug 3;13(1):107
pubmed: 32746880
Angew Chem Int Ed Engl. 2023 Jun 12;62(24):e202303010
pubmed: 37040149
Clin Exp Immunol. 2020 May;200(2):108-119
pubmed: 31828774
Mol Cancer. 2019 Aug 23;18(1):128
pubmed: 31443694